FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 113 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion... July 7, 2022 Regular Exercise May Help Guard Breast Cancer Patients From Chemo Brain August 20, 2021 How targeted screening can help the NHS save lives from lung... November 23, 2022 Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma December 17, 2021 Load more HOT NEWS Radionuclide Therapy Could Be A Viable Treatment For Early-Stage Breast Cancer,... FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease Mom Wants Disney To Ban Childless Adults From Their Theme Parks Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic...
